Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyReferences
- Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.Circ Heart Fail. 2012; 5: 535-546
- Hypertrophic cardiomyopathy.Lancet. 2013; 381: 242-255
- Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.J Am Coll Cardiol. 2014; 64: 83-99
- Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.Circulation. 2001; 104: 2517-2524
- Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy.Curr Cardiol Rep. 2001; 3: 141-146
- Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance.Am J Cardiol. 2014; 113: 1394-1400
- Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.J Am Coll Cardiol. 2002; 39: 301-307
- Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy.Cardiology. 2013; 126: 258-264
- Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation.Am J Cardiol. 1999; 83: 13H-18H
- Alterations in contractile protein composition and function in human atrial dilatation and atrial fibrillation.J Mol Cell Cardiol. 2006; 41: 467-477
- Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.Heart Rhythm. 2015; 12: 1438-1447
- Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy.Mayo Clin Proc. 2008; 83: 630-638
- Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy.Am J Cardiol. 2014; 114: 769-776
- Effects of chronic atrial fibrillation on active and passive force generation in human atrial myofibrils.Circ Res. 2010; 107: 144-152
- Tension generation and relaxation in single myofibrils from human atrial and ventricular myocardium.Pflugers Arch. 2007; 454: 63-73
- Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.Circulation. 2013; 127: 1916-1926
- Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity.Genet Med. 2015; 17: 880-888
- Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.J Am Coll Cardiol. 2012; 60: 705-715
- Genetic advances in sarcomeric cardiomyopathies: state of the art.Cardiovasc Res. 2015; 105: 397-408
- Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.Europace. 2010; 12: 347-355
- Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: long-term outcomes and clinical predictors.J Am Coll Cardiol. 2015; 65: 1485-1487
- Sex differences in myosin heavy chain isoforms of human failing and nonfailing atria.Am J Physiol Heart Circ Physiol. 2014; 307: H265-H272
- Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations.J Am Coll Cardiol. 2014; 64: 2589-2600
- Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization.J Am Coll Cardiol. 2013; 62: 2010-2019
- Reduced junctional Na+/Ca2+-exchanger activity contributes to sarcoplasmic reticulum Ca2+ leak in junctophilin-2-deficient mice.Am J Physiol Heart Circ Physiol. 2014; 307: H1317-H1326
- Ca(2+) leak in atrial fibrillation: junctophilin-2 stabilizes ryanodine receptor.J Am Coll Cardiol. 2013; 62: 2020-2022
- Genetic basis of atrial fibrillation.Curr Opin Cardiol. 2014; 29: 220-226
- Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.Circulation. 2013; 127: 575-584
- Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following an ELectricaL CardiOversion) study.Heart Rhythm. 2015; 12: 872-878
Article info
Publication history
Footnotes
This work was supported by the Italian Ministry of Health: RF 2010 – 2313451 “Hypertrophic cardiomyopathy: new insights from deep sequencing and psychosocial evaluation”, WFR GR-2011-02350583 “Atrial Dilatation as a substrate for Atrial Fibrillation in Hypertrophic cardiomyopathy: cellular mechanisms and novel therapeutic approaches” and NET-2011-02347173 “Mechanisms and treatment of coronary microvascular dysfunction in patients with genetic or secondary left ventricular hypertrophy”.
See page 1157 for disclosure information.